Tarsus Pharmaceuticals
TARS
43 hedge funds and large institutions have $294M invested in Tarsus Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 3 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
6% more capital invested
Capital invested by funds: $277M → $294M (+$16.9M)
0.65% more ownership
Funds ownership: 62.56% → 63.22% (+0.65%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 44 → 43 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$4.46M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$785K |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$261K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.08M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$478K |
| 3 |
Morgan Stanley
New York
|
-$450K |
| 4 |
VEA
Virtus ETF Advisers
New York
|
-$129K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$122K |
TARS Hedge Fund Activity: Q4 2021 in Review
43 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2021, worth a combined $294M — up 6.1% from $277M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TARS and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 17 added.
The largest buyer was JP Morgan Chase, adding an estimated $4.46M. The largest seller was Cormorant Asset Management, cutting an estimated $1.08M.
- 43 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2021, down from 44 in Q3 2021.
- Funds reported $294M of Tarsus Pharmaceuticals stock for Q4 2021, up 6.1% quarter-over-quarter.
- 2 funds opened new Tarsus Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of -1 holder.
- The largest Tarsus Pharmaceuticals buyer in Q4 2021 was JP Morgan Chase, an estimated $4.46M added.
- The largest Tarsus Pharmaceuticals seller in Q4 2021 was Cormorant Asset Management, an estimated $1.08M sold.
Based on aggregated 13F filings for Q4 2021.